The goal of the Functional Genomics Core (FGC) is to provide a comprehensive, integrated approach to genomics research for Cancer Center investigators. Presently, the FGC provides a range of Microarray and Data Analysis Services. The microarray gene expression profiling service is based on the Affymetrix oligonucleotide array platform of GeneChips. Basic and advanced data analysis is provided by biostatisticians and bioinformaticists in conjunction with the Biomedical Informatics Core. The FGC is currently undergoing expansion to provide two new major services, RNAi-based technology and genotyping. The former allows functional analyses of genes using approaches such as siRNA, and latter provides moderate-throughput SNP and DMA methylation analyses. All of the FGC services are provided by highly experienced Core Managers with extensive expertise in their areas of specialization. Cohesiveness and synergy among all of the FGC components are provided by the Scientific Director, who leads regular meetings with all Core Managers to discuss assay development, data analysis, trouble-shooting, integration, and new techniques. The Core Managers provide advice to investigators on experimental design prior to laboratory and clinical studies, assay development and quality control during the studies and interpretation of data generated by the Core. This """"""""one-stop shopping"""""""" approach makes functional genomics research more broadly accessible to Cancer Center investigators. Thus, the FGC provides advanced technologies and support for basic, clinical and population studies that enhance functional genomics research and collaborations across all COHCCC programs. During the prior 12-month reporting period, the FGC was used by 14 Cancer Center members from all 5 Research Programs;peer-reviewed usage represented 76% of the total. The proposed total annual budget is $339,788, representing 39% institutional support, 18% user fees, 16% other, and 27% ($91,000) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-26
Application #
8182245
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-12-01
Budget End
2009-11-30
Support Year
26
Fiscal Year
2009
Total Cost
$30,336
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765
Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923
Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R
Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123
Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60

Showing the most recent 10 out of 1396 publications